Lymphoma Hub Satellite Symposium 2021: Summary and roundtable discussion

On Friday, June 18, 2021, at the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub hosted a...

Satellite Symposium | Sequencing of therapy for a patient with TP53-mutated MCL

The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw...

Satellite Symposium | Sequencing treatment options in primary refractory DLBCL

The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a...

Satellite Symposium | Treatment options for a patient with ibrutinib-resistant CLL

The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML),...

Educational theme | The long-term efficacy and safety outcomes of anti-PD-1 inhibitors for the treatment of R/R cHL

The focus of our educational theme on the Lymphoma Hub this quarter, is...

Which emerging therapies are likely to shape treatment approaches for relapsed MCL?

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston,...

Can ctDNA be used to detect MRD in Hodgkin lymphoma?

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Sven Borchmann, University Hospital Cologne, Cologne, DE. We asked, Can...

Brentuximab vedotin for the treatment of Hodgkin lymphoma

In May 2018, the Lymphoma Hub reported the FDA approval of brentuximab vedotin (BV) for the frontline treatment of patients with...

How does COVID-19 impact patients with lymphoma receiving B-cell-depleting immunotherapy?

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Caroline Besson, Université de Paris, Paris,...

Attenuated responses to COVID-19 vaccination in patients with hematologic malignancies

Patients with hematologic malignancies have an increased risk of infections, due to disease-related immune...

Treatment landscape for mantle cell lymphoma: An update

The virtual Lymphoma Hub Satellite Symposium on the sequencing of therapies in high-risk relapsed/refractory (R/R) lymphoma and chronic...

Immunological effects of ibrutinib for patients with CLL and COVID-19

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries, predominantly affecting older...